Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

100% complete response (CR) rate among all six efficacy evaluable patients Favorable safety profile with no Grade > 3 CRS or ICANS Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease 36 patients